Physician profile
Raphael D Lanade
NPI 1427081884
$562.25
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $35.63 · 2021: $59.98 · 2022: $118 · 2023: $116 · 2024: $24.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $139.44 | 2019 | |
| Amgen INC. | $68.63 | 2022-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $41.46 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $37.87 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.17 | 2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2019-2020 | |
| Abbvie INC. | $25.13 | 2021 | |
| Mylan Specialty L.P. | $22.67 | 2019 | |
| Pfizer INC. | $22.18 | 2021 | |
| Dexcom, INC. | $21.00 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $19.94 | 2022 | |
| Shield Therapeutics INC | $19.08 | 2023 | Accrufer |
| Valeritas, INC. | $18.37 | 2019 | |
| Merck Sharp & Dohme LLC | $13.75 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Lanade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.